We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies as set out in our cookie notice.
What is ADVATE? ADVATE is a medicine used to replace clotting factor (factor VIII or
antihemophilic factor) that is missing in people with hemophilia A. ADVATE is not used to treat von Willebrand disease.1
*In clinical trials, ADVATE has demonstrated the ability to help patients prevent bleeding episodes using a prophylaxis regimen.
For people with hemophilia A, ADVATE has a legacy of treatment experience and provides clinically proven bleed protection.*1,2
Data on file. Takeda Pharmaceutical Company Limited. 2018.
Shapiro AD, Schoenig-Diesing C, Silvati-Fidell L, Wong WY, Romanov V. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A. Haemophilia. 2015;21(6):791-798.
Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20(5):607-615.
Do not use ADVATE if you are allergic to mice or hamsters or are allergic to any ingredients in ADVATE. Tell your HCP if you are pregnant or breastfeeding because ADVATE may not be right for you.
You are now leaving ADVATE.com
Takeda does not review, endorse, or control the content of any non-Takeda site. Takeda is not responsible for the accuracy, content, practices, or standards of any non-Takeda resources accessed through a link on this site.